JPWO2021202825A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202825A5 JPWO2021202825A5 JP2022559934A JP2022559934A JPWO2021202825A5 JP WO2021202825 A5 JPWO2021202825 A5 JP WO2021202825A5 JP 2022559934 A JP2022559934 A JP 2022559934A JP 2022559934 A JP2022559934 A JP 2022559934A JP WO2021202825 A5 JPWO2021202825 A5 JP WO2021202825A5
- Authority
- JP
- Japan
- Prior art keywords
- fenebrutinib
- subject
- acceptable salt
- pharma
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 claims 58
- 229950009618 fenebrutinib Drugs 0.000 claims 58
- 150000003839 salts Chemical class 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 35
- 230000000977 initiatory effect Effects 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 230000003902 lesion Effects 0.000 claims 8
- 239000008177 pharmaceutical agent Substances 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 4
- 108010082126 Alanine transaminase Proteins 0.000 claims 4
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 claims 4
- 210000000133 brain stem Anatomy 0.000 claims 4
- 230000002045 lasting effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000000926 neurological effect Effects 0.000 claims 4
- 230000001953 sensory effect Effects 0.000 claims 4
- 230000000007 visual effect Effects 0.000 claims 4
- 239000004382 Amylase Substances 0.000 claims 2
- 102000013142 Amylases Human genes 0.000 claims 2
- 108010065511 Amylases Proteins 0.000 claims 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims 2
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims 2
- 208000009139 Gilbert Disease Diseases 0.000 claims 2
- 208000022412 Gilbert syndrome Diseases 0.000 claims 2
- 102000004882 Lipase Human genes 0.000 claims 2
- 108090001060 Lipase Proteins 0.000 claims 2
- 239000004367 Lipase Substances 0.000 claims 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims 2
- 235000019418 amylase Nutrition 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 210000001638 cerebellum Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005021 gait Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 235000019421 lipase Nutrition 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US63/005,095 | 2020-04-03 | ||
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| US63/051,767 | 2020-07-14 | ||
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520469A JP2023520469A (ja) | 2023-05-17 |
| JP2023520469A5 JP2023520469A5 (https=) | 2024-04-10 |
| JPWO2021202825A5 true JPWO2021202825A5 (https=) | 2024-04-10 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559934A Pending JP2023520469A (ja) | 2020-04-03 | 2021-04-01 | ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010513A (es) * | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
| KR102933902B1 (ko) | 2021-05-14 | 2026-03-05 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 공결정질 형태 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| MX393601B (es) | 2017-05-18 | 2025-03-21 | Jiangsu Hengrui Medicine Co | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| CN113423401A (zh) | 2019-01-22 | 2021-09-21 | 豪夫迈·罗氏有限公司 | 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 |
| MX2022010513A (es) | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
-
2021
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| JPH10505864A (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| WO2012016549A1 (zh) | 丹参组合物在制备用于冠心病二级预防的药物中的用途 | |
| JP2009534384A (ja) | オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療 | |
| JP2023535744A (ja) | 片頭痛の治療 | |
| CN109316480A (zh) | 组合als疗法 | |
| Popa | Captopril-related (and-induced?) asthma | |
| JPWO2021202825A5 (https=) | ||
| JP2872809B2 (ja) | モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物 | |
| US12090125B2 (en) | Combination therapy | |
| Cass et al. | Hazards of phenylephrine topical medication in persons taking propranolol | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| JPWO2020106927A5 (https=) | ||
| JP6514420B2 (ja) | 睡眠時無呼吸の処置のためのスルチアム | |
| Radauceanu et al. | Use of a prostacyclin analogue in cholesterol crystal embolism | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| NL2034624B1 (en) | Post-COVID treatment | |
| JP7219476B2 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
| RU2022127814A (ru) | Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| JPWO2022125598A5 (https=) | ||
| JP2013511528A (ja) | 喘息の急性憎悪の治療及びそれに罹患した患者の入院の可能性の低減 | |
| WO2025018279A1 (ja) | ヒト移植片対宿主病の治療薬およびその組合せ物 | |
| CN117653637A (zh) | 恩替卡韦的新用途 |